Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.38 |
| ▸ | JAK2 | O60674 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3304440 | 0.86 | PTK2 (0.39) | CHEK1CCNA2CDK2CCNA1PTK2 | |
| SCHEMBL3303806 | 0.85 | HTR2A (0.43) | HTR2AIDH2HTR6CHEK1CCNA2 | |
| SCHEMBL3305310 | 0.82 | CHEK1 (0.43) | CHEK1CCNA2CDK2CCNA1JAK2 | |
| SCHEMBL3300452 | 0.77 | IDH2 (0.57) | IDH2CHEK1CDK2PTK2JAK2 | |
| SCHEMBL3304480 | 0.77 | IDH2 (0.57) | IDH2CHEK1CDK2PTK2JAK2 | |
| SCHEMBL2144921 | 0.77 | CHEK1 (0.49) | HTR2ACHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL2145089 | 0.76 | JAK2 (0.45) | IDH2CHEK1PTK2JAK2JAK3 | |
| SCHEMBL2144375 | 0.76 | JAK2 (0.45) | IDH2CHEK1PTK2JAK2JAK3 | |
| SCHEMBL2144367 | 0.76 | JAK2 (0.45) | IDH2CHEK1PTK2JAK2JAK3 | |
| SCHEMBL3299882 | 0.74 | CHEK1 (0.43) | IDH2CHEK1PTK2JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | HTR2A 1267/4885IDH2 671/4885HTR6 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.